PROCESS FOR PREPARING DIDEOXYINOSINE
USING ADENOSINE DEAMINASE ENZYME

5   This application claims a benefit of priority from U.S. Provisional Application No. 60/451,842, the entire disclosure of which is herein incorporated by reference.

Field of the Invention

The present invention relates generally to a method of making 2',3'-dideoxyinosine (ddI) from 2',3'-dideoxyadenosine (ddA), more particularly, the

10   present invention relates to a method of making ddI using adenosine deaminase enzyme (ADA) derived from a human ADA nucleotide sequence.

Description of the Background Art

Dideoxynucleosides are relatively stable nucleoside analogs. The

15   dideoxynucleoside 2',3'-dideoxyinosine (ddI) has been shown to have useful pharmacological activity as antiviral agents. Hartman, et al., *Clin. Pharmacol. Ther.* 47:647 (1990). In particular, ddI has been shown as useful when used alone or in combination with 3'-azido-2',3'-dideoxythymidine (AZT) in the treatment of AIDS. Use of ddI has become increasingly important in light of the development of AZT

20   resistant strains of human immunodeficiency virus.

Efforts to synthesize dideoxynucleosides in the laboratory have been reported, such as the deoxygenation of nucleosides at the 2' or 3' position. *Chem. Pharm. Bull.*, 22:128 (1974). However, chemical synthesis is difficult due to steric

25   hinderance and the instability of nucleosides under temperature and pH conditions normally required to drive reactions. Furthermore, the starting materials for the synthesis are costly and not available in bulk. To date, it has not been possible to scale up laboratory scale synthesis of dideoxynucleosides to industrial scale commercial production of these compounds.

30

A number of processes are known for industrial scale production of ddI by enzymatic deamination of dideoxyadenosine (ddA) by adenosine deaminase.

EV305487217US

Synthesis of ddI by deaminating 2',3'-dideoxyadenosine using bovine adenosine deaminase has been reported. Webb et al., *Nucleosides & Nucleotides*, 7(2):147-153 (1988). Scale up of a process of synthesizing ddI using bovine adenosine deaminase has also been reported, including optimization of parameters, such as solvents and

5   buffers. *Nucleosides & Nucleotides*, 10(7):1499-1505 (1991).

U.S. Patent No. 5,011,774 to Farina *et al.*, discloses a process in which an anomeric mixture of (D)-2',3'-dideoxyadenosine is reacted with an ADA in a suitable solvent to selectively favor the rate of enzymatic deamination of the more active β-

10   anomer of ddI. The processes uses commercially available ADA derived from calf spleen. This process avoids the steps of chromatographic and crystallization techniques necessary to separate out the undesirable α-anomer. However, a possible disadvantage of using this process is the risk of transmission of Transmissible Spongiform Encephalopathy (TSE) when bovine sources of the enzyme are used.

15

U.S. Patent No. 4,970,148 to Yokozeki *et al.* discloses a process in which 2',3'-dideoxyadenosine (ddA) is contacted with a culture solution of a microorganism containing ADA enzymes capable of converting the ddA to ddI. The process uses a culture solution of whole microorganisms, cell homogenates, or products of cells

20   treated with lysozyme, salt, surface active agents, or the like as the source of the ADA. One disadvantage of this method is that the natural source of the enzyme is inherently unstable at a pH in excess of 8 and requires strict pH control. When performed at a pH less than 8, the product ddI is only soluble in very dilute concentrations (<1% weight volume). As a result, the method produces very little ddI

25   per batch. Furthermore, the ddI so derived must undergo extensive purification procedures to remove residual protein contamination in order to obtain the purified ddI product. These purification procedures are costly and can result in loss of product and reduced yields.

30   Japanese Patent Applications No. 5-219978 to Noguchi *et al.*, discloses a method of producing nucleic acid related substances such as ddI including cloning the gene coding for the appropriate enzyme, constructing an expression vector with

regulatory sequences resulting in high expression of the gene, transforming a microorganism with the expression vector to form a transformant, inducing expression of the cloned gene, and extracting and isolating the enzyme so expressed. The isolated enzyme is then used to produce the desired nucleic-acid-related

5   substance by reaction with a suitable starting material, such as ddA. This method produces a 100 fold increase in the amount of enzyme available for use as compared to the Yokozeki patent. However, the enzymes isolated according to this method are microbial enzymes. As such, at least with respect to the ADA, the enzyme lacks stability at pH values greater than 8. As a result, in order to obtain acceptable yields,

10   the pH must be closely regulated. Furthermore, this method produces a product that is in intimate contact with the ADA. The reaction mixture is contaminated with impurities such as unreacted ddA, nucleic acid by-products as well as the ADA and the product. Consequently, extensive purification methods must be performed in order to isolate the ddI from the reaction mixture. Such purification methods typically

15   require repeated liquid chromatography or thin layer chromatography. These purification procedures are not amenable to commercial scale up.

U.S. Patent No. 4,962,193 to Yokozeki *et al.*, discloses a method of purifying ddI from a process using an enzyme which uses a porous, non-polar resin to adsorb

20   the ddI onto the resin, separating the resin from solution, and fractionally eluting the adsorbed ddI to obtain purified product. However, this method is preceded by treatment to remove proteins and concentrate and filter the solution containing the product prior to the final purification step. As a result, this method can be costly and time consuming.

25

There is a present need for an industrial scale method of making ddI that provides satisfactory yield without the risk of transmission of TSE or the need to undergo extensive purification procedures to remove residual protein, and that uses an enzyme which is stable over a broad pH range.

30

Summary of the Invention

The present invention is generally directed to a method of making ddI by contacting ddA with an enzyme having ddA deaminase activity, which is immobilized on an insoluble support. The present invention provides a method of making

5   didanosine (ddI) including the steps of: (a) obtaining an enzyme expressing ddA deaminase activity; (b) immobilizing the enzyme onto an insoluble support; (c) contacting the enzyme with a dideoxyadenosine (ddA) solution of at least about 4% weight volume ddA in water for a time and under conditions to produce a ddI solution; and (d) isolating the ddI from the ddI solution. Optionally, the resulting ddI

10   mother liquor is reused in subsequent runs to improve yield.

Detailed Description of the Invention

The present invention is directed to methods of making ddI from ddA in a cost effective and reliable manner which avoids the shortcomings of the prior art methods.

15

Previous methods of preparing ddI from ddA involve using commercially available ADA, such as bovine ADA (available from Sigma) or ADA derived from growing *E. coli* transformed with microbial ADA. The methods involve admixture of the enzyme in solution with ddA to convert the ddA to ddI. Next, the ddI must be

20   removed from a solution containing a variety of contaminants, including the enzyme. This requires substantial purification and separation to obtain ddI from the contaminated reaction mixture.

In contrast to these prior art methods, the present invention uses ADA, or

25   other enzyme capable of deaminating ddA, in an immobilized state. The immobilization assists in improving stability of the enzyme in the reaction mixture. More importantly, the immobilization allows for easy separation of the ddI final product from the reaction mixture because a main contaminant, namely the enzyme, remains immobilized on an insoluble support.

30

The invention further provides a new source of ADA. In a preferred embodiment of the invention, ddI is made from ddA using ADA derived from

growing organisms transformed with human ADA or conservative derivatives thereof. One advantage of the present method is that human ADA is more stable than microbial ADA over a broader pH range. When the reaction can be performed at a pH in excess of about 8 the ddA remains stable and conversion efficiency to ddI is

5   improved. An additional advantage is that the ddI remains in solution at these pH's much more readily than at a pH of less than about 8. The characteristic of improved solubility of the product ddI at high pH (>8) helps to enable reaction at higher concentrations, and thus provide improved yields of ddI.

10   The inventive methods use human ADA enzyme or other enzyme having ddA deaminase capability, that has been immobilized onto an insoluble support. The present invention takes useful advantage of the improved stability afforded the enzyme which results from such immobilization. As a result, the reaction of ddA to ddI can proceed at pH ranges that typically denature or otherwise interfere with the

15   activity of the enzyme. Additionally, immobilization of the ADA imparts a convenient characteristic to the ADA, namely the ability to separate the enzyme from the reaction product by simple filtration methods.

Preparing Adenosine Deaminase (ADA)

20   The ADA of particular interest in the present invention is human ADA or a conservative variant thereof, having amino acid sequence SEQ ID NO:1 (Genbank Accession number gi|14043373). The human version of ADA was selected due to its superior structural stability to that of microbial origin. In particular, the human ADA maintains significant activity in a relatively wide pH and range as compared to

25   microbial ADA. Furthermore, the human ADA is more resistant to degradation at elevated temperatures as compared to that of microbial origin. The DNA sequence of the human ADA is published as a cDNA sequence derived from human mRNA which is a 1,533 base sequence. See, Gwendolyn, S. *et al., Mol. and Cellular Biology,* 4(9):1712-1717 (1984).

30

The published sequence, or certain conservative variations thereof, may be used to code for and obtain the desired ADA. SEQ ID NO:2 (Genbank Accession

number gi|14043372) is the published human cDNA sequence. Desirably, especially when using *E. coli* as the host, SEQ ID NO:3 (Genbank Accession number gi|140433732) is used. SEQ ID NO:3 is a conservative variant of the published human cDNA in which codon preference substitutions have been made for arginine,

5   glycine, leucine, isoleucine and proline. As the genetic code is degenerated, these codon substitutions do not result in an alteration of the amino acids coded for by the sequence. Rather, the substitution improves recognition of the codons by *E. coli*. The following codon preference substitutions may be used:

10   **Table 1 - Codon Preference Substitutions**

Amino Acid	Mammalian Codon	Substitute Codon
Arginine	AGG	CGT
"	AGG	CGC
"	CGG	CGC
"	CGG	CGT
"	AGA	CGC
Glycine	GGA	GGT
"	GGG	GGT
"	GGG	GGC
Isoleucine	ATA	ATT
Leucine	TTA	CTG
"	CTA	CTC
"	CTC	CTG
"	CTT	CTG
Proline	CCC	CCG
"	CCA	CCG
"	CCT	CCG
"	CCA	CCG

15   The invention further includes use of sequences including other minor modifications, and all naturally occurring alleles, of the amino acid sequence set forth in SEQ ID NO:1 that result in enzymes which have substantially equivalent activity. Modifications may be deliberate, as by site-directed mutagenesis, or may be spontaneous mutations. Alleles may be from any species. Preferred alleles are of

20   human origin. The invention includes use of all of these polypeptides so long as the activity of the enzyme in deaminating ddA is retained.

For example, the invention also includes conservative variations or equivalent variants of SEQ ID NO:1. The terms "conservative variation" and "equivalent variant" as used herein denote the replacement of amino acids by other amino acids that have similar chemical and biological properties, or that are generally considered equivalent.

For example, it is known in the art to substitute amino acids in a sequence with equivalent amino acids, i.e. conservative variations. Groups of amino acids normally considered to be equivalent are:

Ala (A), Ser (S), Thr (T), Pro (P), Gly (G);

Asn (N), Asp (D), Glu (E), Gln (Q);

His (H), Arg (R), Lys (K);

Met (M), Leu (L), Ile (I), Val (V); and

Phe (F), Tyr (Y), Trp (W).

Substitutions, additions, and/or deletions in the enzyme sequences may be made as long as the function of the ADA used in the methods of the invention is maintained. Equivalent enzymes will normally have substantially the same amino acid sequence as the native enzyme. An amino acid sequence that is substantially the same as another sequence, but that differs from the other sequence by means of one or more substitutions, additions and/or deletions, is considered to be an equivalent sequence, equivalent variant or conservative variation. Preferably, less than 25%, more preferably less than 10%, of the number of amino acid residues in a sequence are substituted for, added to, or deleted from the proteins of the invention.

The human ADA can be prepared by methods known in the art. Such methods include biological synthesis and chemical synthesis. In biological synthesis, the enzyme may be isolated directly from cells. Alternatively, it is known to prepare the enzyme by providing DNA that encodes the enzyme, amplifying or cloning the DNA, expressing the DNA in a suitable host, and harvesting the enzyme. For example, the enzyme may be translated either directly or indirectly from a cDNA encoding the

enzyme amino acid sequence. In chemical synthesis, the four bases are used as raw materials to assemble the known amino acid sequence.

A. Obtaining the Nucleic Acid Sequence which Codes for ADA

5   The DNA encoding the ADA may be derived from an appropriate cDNA library by methods known in the art. See, for example, Gwendolyn, S. *et al.*, Molecular and Cellular Biology, 4(9):1712-1717 (1984), the entirety of which is herein incorporated by reference. The sequence has been assigned GenBank Accession No. GI: 14043372.

10

Generally, the entire DNA strand or additional fragments of the DNA can be isolated by using a known DNA or a fragment thereof as a probe. To do so, restriction fragments from a genomic or cDNA library may be identified by Southern hybridization using labeled oligonucleotide probes. For example, DNA encoding the

15   enzyme can be isolated from human homogenated tissue by using a fragment of the known sequence to prepare one or more oligonucleotide probes. The probe is labeled and used to screen a genomic or cDNA library in a suitable vector, such as phage lambda. The cDNA library may be prepared from mRNA by known methods, such as those described in Gubler and Hoffman, *Gene*, 25:263-270 (1983). Oligonucleotide

20   probes can be used to screen cDNA libraries from different tissues. The oligonucletide probe should be labeled so that it can be detected upon hybridization to DNA in the library being screened. These methods are well known in the art. The DNA isolated is sequenced, and the sequence used to prepare additional oligonucleotide probes. This procedure may be repeated to obtain overlapping

25   fragments until a complete open reading frame is produced.

Methods for DNA amplification and cloning are well known in the art. See, for example, Sambrook and Russel, Molecular Cloning A Laboratory Manual, 3rd Ed., Cold Spring Harbor Laboratory, New York (2001), the entirety of which is herein

30   incorporated by reference. It is convenient to amplify the clones in the lambda-gt10 or lambda-gt11 vectors using lambda-gt10 or lambda-gt11-specific oligomers as the amplimers (available from Clontech, Palo Alto, CA). Other amplification procedures

that are well known in the art such as ligase chain reaction (LCR), Repair Chain Reaction (RCR), and PCR oligonucleotide ligation assay (PCR-OLA) can also be used to amplify the nucleic acids of the invention.

5   As an alternative to the aforementioned biological synthesis of the gene, it is possible to chemically synthesize the gene, based on the reported DNA sequence using methods known in the art.   Such methods include those described in "Modern machine-aided methods of oligonucleotide synthesis", Brown T and Dorcas, J.S., In Oligonucleotide and Analogues a Practical Approach, Ed. F. Eckstern, IRL Press,

10   Oxford UK (1995), the entirety of which is herein incorporated by reference. DNA can also be synthesized by preparing overlapping double-stranded oligonucleotides, filling in the gaps, and ligating the ends together. See, generally, Sambrook *et al.*, and Glover, D.M. and Hames, B.D., eds. Cloning, 2nd Ed., Vols. 1-4, IRL Press, Oxford, UK (1995).

15

In the event there is any concern regarding potential viral contamination related to human sources of DNA, such as for compliance with regulatory requirements, then the chemical synthesis method of obtaining the DNA is preferred.

20   **B.   Expressing the ADA**

The recombinant DNA molecules, obtained as described above, contain polynucleotide sequences encoding human ADA. This recombinant DNA may be cloned in a suitable host cell and expressed by methods well known in the art. Generally, the cloned gene is provided with expression vectors which direct

25   expression of the enzyme in an appropriate host cell. The enzyme may be then be recovered from the host cell. See, Sambrook *et al.* (2001), for methods relating to the manufacture and manipulation of nucleic acids.

The amplified or cloned DNA can be expressed in a suitable vector, preferably

30   an expression vector, by methods known in the art. See, generally, Sambrook *et al.* (2001). Expression vectors are capable of directing the expression of genes to which they are operably linked. Expression vectors of utility in recombinant DNA

9

techniques are often in the form of plasmids. However, the invention may include other forms of expression vectors, such as viral vectors (e.g., replication defective retroviruses, adenoviruses, and the like), which serve equivalent functions. Preferably, the expression vector is a plasmid, as disclosed in U.S. Patent No.

5   6,068,991, the entirety of which is herein incorporated by reference.

Vector DNA, preferably in the form of expression vectors including regulatory sequences, can be introduced into prokaryotic or eukaryotic host cells via conventional transformation or transfection techniques. As used herein, the terms

10   "transformation" and "transfection" are intended to refer to a variety of art-recognized techniques for introducing foreign nucleic acid into a host cell, including calcium phosphate or calcium chloride co-precipitation, DEAE-dextran-mediated transfection, liposome mediated transfection (lipofection), or electroporation. Suitable methods for transforming or transfecting host cells can be found in Sambrook, *et al.* (*supra*), and

15   other laboratory manuals.

The expression vectors preferably contain at least one expression control sequence that is operatively linked to the DNA sequence or fragment to be expressed. The control sequence is selected on the basis of the host cells to be used for

20   expression and inserted in the vector in order to control and to regulate the expression of the cloned DNA sequence.

Within a recombinant expression vector, "operably linked" is intended to mean that the nucleotide sequence of interest is linked to the regulatory sequence(s) in a

25   manner which allows for expression of the nucleotide sequence (e.g., in an *in vitro* transcription/translation system or in a host cell when the vector is introduced into the host cell).

The term "regulatory sequence" is intended to include promoters, enhancers

30   and other expression control elements (e.g., polyadenylation signals). Such regulatory sequences are described, for example, in Goeddel, <u>Gene Expression Technology:</u> <u>Methods in Enzymology</u>, 185, Academic Press, San Diego, CA (1990). Regulatory

sequences include those which direct constitutive expression of a nucleotide sequence in many types of host cells and those which direct expression of the nucleotide sequence only in certain host cells (e.g., tissue-specific regulatory sequences).

5   Examples of useful expression control sequences are the *lac* system, the *trp* system, the *tac* system, the *trc* system, major operator and promoter regions of phage lambda, the control region of fd coat protein, the glycolytic promoters of yeast, e.g., the promoter for 3-phosphoglycerate kinase, the promoters of yeast acid phosphatase, (e.g., Pho5), the promoters of the yeast alpha-mating factors, and promoters derived

10   from polyoma, adenovirus, retrovirus, and simian virus, e.g., the early and late promoters or SV40, and other sequences known to control the expression of genes of prokaryotic or eukaryotic cells and their viruses or combinations thereof.

Examples of suitable inducible non-fusion *E. coli* expression vectors include

15   regulatory sequences such as pTrc (Amann et al., (1988) *Gene* 69:301-315) and pET 11d (Studier et al., Gene Expression Technology: Methods to Enzymology 185, Academic Press, San Diego, California (1990)). Target gene expression from the pTrc vector relies on host RNA polymerase transcription from a hybrid trp-lac fusion promoter. Target gene expression from the pET 11d vector relies on transcription

20   from a T7 gn10-lac fusion promoter mediated by a co-expressed viral RNA polymerase (T7 gn1). This viral polymerase is supplied by host strains BL21(DE3) or HMS174(DE3) from a resident lambda prophage harboring a T7 gn1 gene under the transcriptional control of the lacUV 5 promoter.

25   Suitable host cells can be any prokaryotic (e.g., *E. coli*) or eukaryotic cell (e.g., insect cells, yeast or mammalian cells). Some suitable prokaryotic hosts include, for example, *E. coli*, such as *E. coli* SG-936, *E. coli* HB 101, *E. coli* DH5α, *E. coli* X2282, *E. coli* DHI, and *E. coli* MRCl, *E. coli* BL21, *Pseudomonas* sp., *Bacillus* sp., such as *B. subtilis*, and *Streptomyces* sp. Suitable eukaryotic cells

30   include yeasts and other fungi, insect, animal cells, such as COS cells and CHO cells, human cells and plant cells in tissue culture. Preferably, the host cell is *E. coli*.

It will be appreciated by those skilled in the art that the design of the expression vector can depend on such factors as the choice of the host cell to be transformed, the level of expression of protein desired, and the like. The expression vectors of the invention can be introduced into host cells to thereby produce ADA,

5 including fusion proteins or peptides, encoded by nucleic acids as described herein.

Often, in fusion expression vectors, a proteolytic cleavage site is introduced at the junction of the fusion moiety and the recombinant protein to enable separation of the recombinant protein from the fusion moiety subsequent to purification of the

10 fusion protein. Such enzymes, and their cognate recognition sequences, include Factor Xa, thrombin and enterokinase. Typical fusion expression vectors include pGEX (Pharmacia Biotech Inc; Smith and Johnson (1988) *Gene* 67:31-40), pMAL, (New England Biolabs, Beverly, MA) and pRIT5 (Pharmacia, Piscataway, NJ) which fuse glutathione S-transferase (GST), maltose E binding protein, or protein A, respectively,

15 to the target recombinant protein.

One strategy to maximize recombinant protein expression in *E. coli* is to express the protein in a host bacteria with an impaired capacity to proteolytically cleave the recombinant protein (Gottesman, Gene Expression Technology: Methods

20 in Enzymology 185, Academic Press, San Diego, California (1990) pp. 119-128). Another strategy is to alter the nucleic acid sequence of the nucleic acid to be inserted into an expression vector so that the individual codons for each amino acid are those preferentially utilized in *E. coli* (Wada et al. (1992) *Nucleic Acids Res.* 20:2111-2118). Such alteration of nucleic acid sequences of the invention can be carried out

25 by standard DNA synthesis techniques or site-specific mutagenesis.

The cells are grown under conditions well known in the art. Expression of the cloned gene is induced to express large amounts of the enzyme. Preferably, an *E. coli* expression vector is used including the *lac* system promoter system. Expression of

30 ADA is preferably induced using IPTG.

C.   Isolation and Purification of ADA

Generally, enzymes can be isolated from a solubilized cell fraction by standard methods. Some suitable methods include precipitation and liquid chromatographic protocols such as ion exchange, hydrophobic interaction, and gel filtration. See, for

5   example, Methods Enzymol. - Guide to Protein Chemistry, Deutscher, Ed., Section VII pp. 182-309 (1990); and Scopes, Protein Purification, Springer-Verlag, New York (1987), which are herein incorporated by reference.

Alternatively, purified material is obtained by separating the enzyme on

10   preparative SDS-PAGE gels, slicing out the band of interest and electroeluting the protein from the polyacrylamide matrix by methods known in the art. The detergent SDS is removed from the protein by known methods, such as by dialysis or the use of a suitable column, such as the Extracti-Gel column from Pierce. Mixtures of enzymes can be separated by, for example, SDS-PAGE in accordance with the method of

15   Laemmli, *Nature* 227:680-685 (1970). Such methods are well known in the art.

There are no particular limitations to the method of purifying the protein so long as undesirable contamination is effectively removed. An economical method is to break down the cells by passing the fermentation broth through a microfluidizer to

20   release the enzyme from the cells. Addition of a filter aid and a flocking agent (e.g., PEI, available from VWR International, South Plainfield, NJ) to the stirred broth renders the contaminants such as proteins and other cellular debris insoluble. A suitable filter aid is CELITE (available from World Minerals, Inc., Santa Barbara, CA). The soluble enzyme may then be removed from the broth by filtration with an

25   appropriately sized filter. Desirably, the filter will allow the soluble active enzyme to pass through while allowing insoluble fractions of cellular proteins and other contaminants to be retained by the filter. The enzyme can then be concentrated in solution using an ultrafilter. A 30,000 molecular weight cut off (MWCO) filter is useful for this purpose.

30

Assay ADA Activity

The enzyme so derived should be assayed for activity. As used herein, a unit (U) of enzymatic activity is that amount of enzyme which will deaminate 1 μmol of ddA per minute at 37°C. Desirably, the final enzyme titer is from about 650-750

5   U/ml. The assay may be performed by adding enzyme to a 2.4% solution of ddA at 37°C. The reaction is allowed to proceed for 15 min while gently stirring. Tetrahydrofuran is added to stop the reaction. A sample is taken and run on HPLC to determine the amount of ddI formed.

10   **Immobilizing ADA**

Once the enzyme is purified, it is desirable to treat the enzyme solution with an appropriate buffer to a pH of about 7.3 to about 7.6. There are no particular limitations to the type of buffer used, although phosphate buffer is preferred. Desirably, the solution is diluted with buffer to an activity of from about 250 to about

15   350 U/ml.

The purified enzyme is first immobilized onto a support that is insoluble in the reaction solution before reaction with ddA. There are no particular limitations as to the type of support used so long as the enzyme may be immobilized thereon. In

20   general, the aforementioned dilute solution of buffered enzyme is added to a solution containing an insoluble support, some of which require activation by an activating agent such as a crosslinking reagent. The crosslinking reagent serves to covalently bond the ADA to the support via an amine group on the ADA.

25   The support remains insoluble, and maintains the enzyme insoluble in the reaction solution, during the course of the reaction. Desirably, the support is a solid resin material having a diameter of about 250-600 microns. Suitable supports include, for example, IPS-400 (available from U.O.P., Des Plaines, IA) or EUPERGIT (available from Rohm America Inc, Piscataway, NJ).

30

There are no particular limitations to the crosslinking agent as long as it covalently attaches the enzyme to the support. Selection of crosslinking agents will

depend on the support selected and will be readily apparent to those having skill in the art. Suitable combinations of resin support and crosslinking agents are Celite and glutaraldehyde, IPS-400 and glutaraldehyde, Sepharose and CNBr and resin supports functionalized with either primary amines or carboxyls and carbodiimides. Other

5   appropriate combinations of solid and crosslinking reagents will be apparent to those having ordinary skill in the art.

The immobilization of enzyme onto the support may be performed in a batch or continuous process. A batch process may be performed, for example, by mixing

10   the buffered enzyme solution with activated support for a number of hours. The immobilized enzyme is then collected using a simple filtration technique. The particle retention size will be determined by the size of the solid support. For use with IPS-400, a filter having a particle size retention of from about 20 µm to about 30 µm is useful. Vacuum may be applied to speed recovery, however the support should

15   not be dried.

Alternatively, the activated support can be collected on a filter with particle retention size sufficient to retain the solid support. The buffered enzyme solution is then passed over the support. The enzyme mother liquor from the filtration will be

20   passed through the filter repeatedly to maximize immobilization of the enzyme. In a continuous process, the solid support may be slurried and poured into a chromatography column. After recovery the immobilized enzyme is rinsed with water to remove any impurities or unbound enzyme. Preferably, a titer of the immobilized enzyme is at least about 40U.

25

Reacting ddA with ADA

The immobilized ADA is then admixed with a ddA solution to obtain ddI. During reaction of ddA to ddI, ammonia is generated. Since ddA is added to the enzyme in more concentrated solutions than in the prior art, the ammonia byproduct in the mixture can cause the pH to be elevated in a range of from about 9.2 to about 9.5. Use of microbial ADA or unbound ADA under these conditions is not expected to proceed to completion because the enzyme will become inactivated at these elevated pH's. However, use of the human version of the ADA immobilized on a solid support diminishes such degradation. As a result, the ADA retains activity and the reaction proceeds at a faster, more productive pace, than has heretofore been possible.

The reaction is performed at a temperature of from about 20°C to about 50°C. Desirably, the reaction is maintained at a temperature of about 25-30°C. The reaction can be performed at lower temperatures, however this will result in a longer reaction time. Performing the reaction at temperatures in excess of about 50°C can result in impairment of enzymatic activity and/or denaturing of the enzyme.

Commercially available ddA (available from Ajinomoto, Tokyo, Japan) is added to the immobilized ADA in water in a batch or continuous bulk process. The reaction may proceed using concentrations of ddA well above those used in methods in which the ADA is not immobilized. An acceptable range of concentration of ddA in the reaction solution is from about 1% to about 15%. Desirably, a solution of about 4% to 10% of ddA, more desirably a solution of about 5-6% ddA in water is added to the immobilized ADA. The reaction is allowed to proceed under conditions and for a time so that until about 1% or less of the ddA remains.

In a batch process, the ddA will be added to a suspension of immobilized ADA in water and allowed to react. Complete reaction should take about 5 to 8 hours. Once completed, the immobilized ADA can be recovered for reuse by filtration followed by washing with water. Furthermore, the mother liquor, after removal of ddI product, can be reused to maximize yield.

In a continuous process, a ddA solution may be added to a column packed with immobilized ADA. Desirably, the height to diameter ratio will be about 6, although the ratio is not critical. The ddA solution will be added at a rate and for a time so that about 1% or less of the ddA remains. Complete reaction should take

5   about 120 hours. The flow rate will be dependent on the size of the column, concentration of ddA, and temperature of the reaction. Alternatively, a continuous process may be used in which the ddA solution is recycled through the packed column. The ddA solution will be recycled at a rate and for a time so that about 1% or less of the ddA remains. The flow rate will be dependent on the size of the column,

10   concentration of ddA, and temperature of the reaction. Selection of the rate of introduction of ddA solution will be readily apparent to those of skill in the art.

Recovering ddI

After reacting the ddA to ddI, the ddI is present in solution in the form of an

15   ammonium salt at high pH (>8). In the recovery step, the ddI is removed from solution. This is achieved by crystallizing the ddI out of solution. A simple distillation process may be used to drive off ammonia, a side product of reaction and produce the free acid form of ddI. The distillation can be performed sequentially with a first distillation bringing the solution to a concentration of about 10-12% (based on

20   initial ddA) followed by addition of water and further distillation until the concentration again reaches about 10-12% and the pH of the ddI slurry is less than about 8. The suspension may then be cooled to about 0-5°C and held for at least one hour.

25   The ddI can be filtered and the cake washed with acetone. The solids may then be dried to a constant weight, for example under vacuum at about 45-50°C. Desirably, the reaction mother liquor may be retained for reuse in the batch or continuous processes reacting ddA to ddI. Additionally, the aqueous wash may also be reused.

30

Yields of about 82% may be obtained without any recycling. However, when the reaction mother liquor is recycled, yields can be increased to about 96-99%. The resulting ddI is greater than 99% pure.

5   The following Examples are intended to show the practice of the invention and are not intended to restrict the scope of the present invention. All percentages are in weight/volume unless otherwise indicated.

The entire disclosure of each document cited (including patents, patent
10   applications, journal articles, abstracts, laboratory manuals, books, Genbank Accession numbers, SWISS-PROT Accession numbers, or other disclosures) in the Background of the Invention, Detailed Description, Brief Description of the Figures, and Examples is hereby incorporated herein by reference in its entirety. Further, the hard copy of the Sequence Listing submitted herewith, in addition to its
15   corresponding Computer Readable Form, are incorporated herein by reference in their entireties.

Example 1
Preparation of recombinant *E. coli* transformed with
20   **a human adenosine deaminase (ADA) gene**

E. coli expression plasmid, pBMS2000, was digested with restriction enzymes, BspHI and BamHI, and fractionated on 0.7% agarose gel. The fragment corresponding to the 4.5 Kb was excised from the gel, eluted, concentrated by ethanol
25   precipitation. The synthetic human ADA DNA was excised from the plasmid containing the gene coding for the human ADA gene with the restriction enzymes, Nco I and BamHI. . The NcoI-Bam HI fragment containing the synthetic human ADA gene was ligated to the 4.5Kb fragment of pBMS2000 obtained by digestion with the restriction enzymes, BspHI and BamHI. The ligated DNA was transformed into *E.*
30   *coli* host, BL21. The transformed cells were plated onto Lauria Broth agar plates supplemented with 30µg of neomycin sulfate. Restriction enzyme analysis was performed on some of the colonies as well as SDS-PAGE analysis. One of the

colonies with the correct restriction analysis and the enzymatic activity was selected to be carried forth.

Example 2

Fermentation of recombinant *E. coli* containing

5

the synthetic human adenosine deaminase gene

Fermentation Medium Formulations

Seed medium (per 100 ml)

Reagent	Amount
Soytone	1 g
Yeast extract	0.5 g
NaCl	0.16 g
Neomycin sulfate (657mg/g)	2.0 mg

10

Base medium (per liter)

Reagent	Amount
K_2HPO_4	14 g
Citric acid	2 g
Yeast extract	3.2 g
NaCl	1.6 g
$MgSO_4$-$7H_2O$	2.2 g
Neomycin Sulfate	18 mg
Glycerol	3.4 ml
PPG	0.2 ml

Feed medium (per liter)

Reagent	Amount
Cerelose	200 g
Yeast extract	100 g
Neomycin sulfate	18 mg

15

PH Control - Base

Reagent	Amount
Concentrated NH_4OH	250 ml
H_2O	750 ml

PH Control - Acid

Reagent	Amount
85 % Phosphoric acid	200 ml
Water	800 ml

20

A. Preparation of seed stock

0.2ml of thawed recombinant *E. coli* is inoculated into a 500 ml Erlenmeyer flask containing 100 ml of the seed medium as described above. This is incubated by shaking the flask in a gyratory incubator at 300 rpm at 28°C for 24 hours to prepare

5   an inoculum.

B. Fermentation

50 ml of the inoculum is inoculated into a 5 liter fermenter having a 1 liter working volume. Operating conditions are: a temperature of 28°C; 1000 rpm

10   agitation; aeration of 1 vvm; dissolved oxygen (DO) setting is recorded and defined at 100%; pH controlled with NH_4OH and phosphoric acid to pH 6.8 to 7.2.

2 liters of the feed medium is prepared as follows. Ramp feeding is initiated after 6 hours using a feeding rate of 5 ml/hr increasing at 1.2 ml/hr/hr. The cells are

15   allowed to grow for 24 hours with monitoring. Air flow, feed rate, and temperature are adjusted as required to control DO to greater than or equal to 20% of the initial setting. The temperature of the culture is then decreased to 16°C. The cells are induced with isopropyl β-D-thiogalactoside (IPTG) to the final concentration of 80 μg/ml between 16-18 hours post-inoculation. The optical density at 600 nm is

20   between 20-30. Monitoring and feeding is continued for 40-48 total hours or until the feed is utilized. The broth contains 84 units/ml of solution. (1 unit (U) = 1 μmol of ddA deaminated/min at 37 °C).

Example 3

25   **Isolation and immobilization of the human ADA**
from the recombinant *E. coli* fermentation

10 L of fermentation broth is passed through a microfluidizer (M-110Y model, available from Microfluidics, Newton, MA). Operating pressure is at 12,000-20,000

30   psi until at least 90% of the activity is released from the cell. Activity is measured by taking a portion of the microfluidized broth, centrifuging the sample, and measuring the activity in the supernatant portion. The amount of activity in the supernatant

represents the amount of activity released. Normally one pass through the microfluidizer is required.

5   To 10 L of well-stirred microfluidized broth, is added 1.5 kg of CELITE (final concentration 15% w/v). Then, 0.30 L of 10 % aqueous polyethyleneimine (PEI) (final concentration 0.3% v/v) is added. This is stirred for at least 30 minutes then filter to remove the insolubles. The cake is washed with 3.0-4.0 L of water.

10   The clarified filtrate is ultrafiltrated through a 30,000 MWCO filter cassette (Pellicon 2 unit, polyethersulfone low protein binding cassette, 0.5 m^2 filter area, available from Millipore, Bedford, MA) to a final enzyme titer of between 650-750 U/ml. The sample is diluted with 1.25 L of 50 mM phosphate buffer pH 7.3-7.6 (to an enzyme activity of 250-350 U/ml).

15   To 550g IPS-400 protein immobilization support, is added 2.75 L of 2.5% glutaraldehyde. This is gently stirred at room temperature for 2 hours and decanted or filtered onto a size 60 mesh filter. The activated support is washed 10 times with 4 L water.

20   To the diluted enzyme solution (~0.95L) is added 1.10 kg activated IPS-400 immobilization support and gently stirred for 2 hours at 20-25 °C. The immobilized enzyme is collected on a filter having an effective pore size sufficient to retain the immobilization support and washed with 5 volumes of water.

25   Alternatively, the IPS-400 is slurried in tap water and collected on a Buchner funnel fitted with fast flow filter paper with 20 to 30 µm particle size retention (grade 604 or 415). Vacuum is applied to remove excess water but the support is not dried. The diluted enzyme is added to the resin, vacuum (20" Hg) is applied and the mother liquor collected. Vacuum is stopped, the mother liquor sampled (pass #1) for activity
30   then added back to the support and vacuum is reapplied. This is repeated four more

times for a total of five passes over the IPS-400. After the 5th pass, 1.5 L of water is added to the resin and vacuum applied to wash the immobilized enzyme.

As another alternative, the IPS-400 is slurried in tap water and poured into a chromatography column. The bed is allowed to settle, then water is passed through the column (up flow) to rinse the support. The diluted enzyme solution is pumped through the column (1 to 25 ml/min.). After addition of the enzyme, 1.5 L of water is pumped over the column to wash the immobilized enzyme.

The immobilized enzyme assays show an enzymatic activity of ~100U/g. (1 unit = 1μmol of ddA deaminated/min at 37°C).

Example 4
Preparation of ddI from ddA using the recombinant human ADA immobilized enzyme (batch)

100.0 g ddA is added to 1900 ml of water at 30 °C (mother liquor from previous runs can also be used). After the ddA has been added (complete dissolution is not necessary), 4000 U of immobilized rec human adenosine deaminase is added. The reaction is maintained at 30 °C while stirring. The reaction is complete (approximately 5-8 hours) when the level of residual ddA is less than or equal to 1% of the original amount of ddA added. The enzyme solids are removed by filtration (20-30 μm media) and the enzyme cake is washed with 100 ml water. The used enzyme is held as a wet cake at 0-5 °C (for up to 72 hours) and can be recycled to another batch. The ddI solution is filtered through a CUNO filtration pad (0.4 to 1 micron), then through 0.2 micron filter media.

Example 5

Preparation of ddI from ddA using the recombinant human ADA immobilized enzyme (continuous column)

5   A column (h/d ratio=6) is slurry packed with 380 U of immobilized rec human adenosine deaminase with water. The column is washed with 30 mM of NH_4OH to pH 9.5 then with water to pH 6.5-7.5. While maintaining the temperature at 20 °C, a 4 % solution of ddA in water is passed through the column at a rate of 7.2 ml/min. for 120 hours. The effluent from the column is at pH 9.2-9.5 and contains >99% ddI with

10   <1% ddA remaining. The resulting ddI solution is filtered through a CUNO pad and a 0.2μ filter before final isolation.

Example 6

Preparation of ddI from ddA using the recombinant human ADA

15   ### immobilized enzyme (recycle column)

A column (h/d ratio=2.7) is slurry packed with 1000 U of immobilized rec human adenosine deaminase with water. 25.0 g of ddA is dissolved in 475 ml of water (or a mother liquor from previous batch, diluted with water to 475 ml) at 30 °C

20   in a 3-neck round bottom flask equipped with a mechanical stirrer. The ddA solution is circulated at 30 °C through the enzyme column at ~50mL/min (circulation speed can be varied as necessary).

The reaction is complete (approximately 3-9.5 hours) when the level of

25   residual ddA is less than or equal to 1 % of the original amount of ddA added by HPLC analysis. The column is then rinsed with 25 ml of water and can be held at 0-5 °C (for up to 72 hours) for reuse. The resulting ddI solution is filtered through a CUNO pad and a 0.2 μm filter before final isolation.

Example 7

Isolation of ddI

The ddI solution is distilled under vacuum at an internal batch temperature of

5   20-40 °C. The distillation is stopped when the concentration of ddI reaches 10-12 %

w/v based on initial ddA. Typically the pH is 8.1-8.3 at this point. Additional water

is added and distillation is then continued until the concentration again reaches 10-12

%, and the pH of the ddI slurry is less than 8 (typically 7.8-7.9). The ddI suspension

is cooled to 0-5 °C and held for at least 1 hour. The cold slurry is filtered and the

10   cake is washed with 0-5 °C water. The mother liquor and aqueous wash can be

retained for recycling in another batch.

The cake is washed with 0-5°C acetone. The solids are dried under vacuum at

45-50°C to a constant weight. Yields of ~82 % for the first run and 96-99 % for four

15   subsequent runs (>96 % overall) are expected with mother liquor recycling. The

resulting ddI is >99 % pure.

Comparative Example 1

Comparison of E. coli ADA activity and recombinant human immobilized ADA

20

Microbial ADA from recombinant *E. coli* was partially purified and isolated as

an ammonium sulfate suspension. *E. coli* fermentation broth (42U ADA/mL, 2 L)

was centrifuged and the cell pellet was collected and washed with 1 L 100 mM

phosphate buffer pH 7.5. The cells were again centrifuged and resuspended in 2 L of

25   the above buffer plus 20% glycerol. The cells were passed once through a

microfluidizer. Cell debris was removed by centrifugation and the resulting

supernatant was concentrated by ultrafiltration through a 30,000 MWCO cassette.

The enzyme was concentrated to a final titer of 390U/ml. Ammonium sulfate was

added to a 50% saturation, the resulting precipitate was collected by centrifugation

30   and re-suspended in 100 ml deionized water. The final titer of the slurry was

740U/ml; the protein content of the slurry was ~75 mg/ml.

The following Table describes the conversion of a 52-60g/L solution of ddA in water to ddI using the microbial adenosine deaminase as described above versus an example using the recombinant human ADA immobilized enzyme following the general procedure in Example 4. As can be seen from the results of **Table 2**, the recombinant human immobilized enzyme is significantly more stable than microbial enzymes and allows for the completion of the reaction with less units of enzyme and in a short period of time.

Table 2 - Comparative Yields of ddA from *E. coli* Versus Recombinant Human ADA

Source of ADA	Enzymatic Activity (U/g ddA)	Reaction Temperature (°C)	Reaction Time (hours)	Conversion of ddA to ddI (%)
E. coli $(NH_4)_2SO_4$ suspension	87.5	40	16	16
E. coli $(NH_4)_2SO_4$ suspension	125	37	24	26
Recombinant human immobilized ADA	40	30	4.5	100
Recombinant human immobilized ADA	40	40	1.5	100

Thus, while there have been described what are presently believed to be the preferred embodiments of the present invention, other and further embodiments, modifications, and improvements will be known to those skilled in the art, and it is intended to include all such further embodiments, modifications, and improvements and come within the true scope of the claims as set forth below.